早期非小细胞肺癌立体定向体部放疗:ASCO对ASTRO循证指南的背书
ASCO专家小组对ASTRO 2017年早期非小细胞肺癌立体定向体部放疗循证指南进行方法学审查并更新文献检索,认为推荐清晰、全面且基于最相关科学证据,并加入ASCO声明和细微修改以增强适用性。指南明确标准手术风险I期NSCLC患者不推荐临床试验外使用SBRT,肺叶切除加系统淋巴结评估仍是推荐治疗。
要点
- 标准手术风险I期NSCLC患者,临床试验外不推荐SBRT,肺叶切除加系统淋巴结评估仍是推荐治疗。
- 特定临床场景下可考虑亚肺叶切除。
- 高危或无法手术患者,指南提供SBRT使用推荐,涵盖中央型、>5cm、无组织诊断等挑战性场景。
核心结论
- ASCO专家小组认可ASTRO 2017年早期NSCLC SBRT循证指南推荐清晰、全面且基于最相关科学证据。
- 标准手术风险I期NSCLC患者,临床试验外不推荐SBRT,肺叶切除加系统淋巴结评估仍是推荐治疗。
研究设计与样本
- ASCO对ASTRO循证指南进行方法学审查,专家小组更新文献检索并审阅指南内容和推荐。
主要发现
- ASCO专家小组确定ASTRO指南推荐清晰、全面且基于最相关科学证据。
- ASCO添加声明和细微修改以增强ASTRO指南对更广泛ASCO受众的适用性。
关键数值与推荐
- 标准手术风险I期NSCLC患者,临床试验外不推荐SBRT。
- 肺叶切除加系统淋巴结评估仍是推荐治疗,特定临床场景可考虑亚肺叶切除。
- 指南提供高危手术风险患者和无法手术患者使用SBRT的推荐,包括中央型、>5cm、无组织诊断、同时性原发或多灶、全肺切除后第二原发、邻近或侵犯纵隔结构、紧贴胸壁或既往治疗后复发等挑战性场景。
临床怎么用
- 标准手术风险I期NSCLC患者应优先考虑肺叶切除加系统淋巴结评估,临床试验外不推荐SBRT。
- 高危或无法手术患者可参考指南推荐使用SBRT,包括多种挑战性场景。
- 治疗选择应经多学科癌症治疗团队讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on treatment with stereotactic body radiotherapy (SBRT) for patients with early-stage non-small-cell lung cancer. ASCO has a policy and set of procedures for endorsing and/or adapting clinical practice guidelines that have been developed by other professional organizations. Methods The ASTRO Evidence-Based Guideline for Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer was reviewed for developmental rigor by methodologists. An ASCO Expert Panel updated the literature search and reviewed the guideline content and recommendations. Results The ASCO Expert Panel determined that the recommendations from the ASTRO guideline, published in 2017, are clear, thorough, and based on the most relevant scientific evidence. ASCO statements and minor modifications were added to enhance the applicability of the ASTRO guideline for the broader ASCO audience. Recommendations For standard operative risk patients with stage I NSCLC, SBRT is not recommended outside of a clinical trial. Lobectomy with systematic lymph node evaluation remains the recommended treatment, although a sublobar resection may be considered in select clinical scenarios. Recommendations are provided regarding the use of SBRT in high operative risk patients and for inoperative patients, including in challenging scenarios where tumors are: centrally located, > 5 cm in diameter, lacking tissue diagnosis, synchronous primary or multifocal, second primary after pneumonectomy, proximal to or involved with mediastinal structures, abutting the chest wall, or recurring after previous treatment. Qualifying statements are included to provide further guidance for implementation, and the importance of a discussion of treatment options among members of the multidisciplinary cancer care team is emphasized. Additional information is available at: www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki .
引用
- Schneider BJ, Daly ME, Kennedy EB, et al. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. 2017. PMID: 29106810. doi:10.1200/JCO.2017.74.9671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。